First-in-Class Products
Multiple MOA's
Product Strengths
Clinical Pipeline
Product Discovery
Partnerships
Executive Management Team
Advisors
Jennerex Story
Career Opportunities
Press Releases
Jennerex in the News
Events
Company
Patients
Gateways
News
FAQs
Contact Us
Site Map
Search
01/11/10
Jennerex Appoints Dr. Hoyoung Huh to Its Board of Directors
12/23/09
Jennerex Announces Presentations at Upcoming Conferences
11/18/09
Jennerex and Lee’s Pharmaceuticals Announce Partnership jor JX-594 in China
10/19/09
Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
09/18/09
Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
Clinical Trial Programs with Lead Product Jx-594 Funded Through 2010
08/11/09
Jennerex Closes $5 Million First Tranche of Series C Financing
Clinical Trial Programs Funded Through 2010
06/11/09
Jennerex Therapeutic Research Collaboration with Ottawa Hospital Research Institute Selected for $10 Million Grant from Ontario Institute for Cancer Research
02/10/09
Nature Reviews
Publishes Article about Jennerex’s Multi-mechanistic Cancer Therapeutic
01/13/09
Jennerex Appoints Samantha Miller as Vice President of Corporate Development
01/12/09
Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
11/04/08
Jennerex To Present at Rodman & Renshaw 10th Annual Healthcare Conference
10/15/08
Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial with Intravenous Delivery of JX-594 Oncolytic Virus
09/09/08
Jennerex Completes $8.3 Million Series B Financing and Appoints
Dr. Cal Stiller as Director
07/16/08
Jennerex Publishes Clinical Trial Data with Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated
Hepatitis B Virus
06/02/08
Jennerex Clinical Trial Data with JX-594 Selected for Plenary Session Presentation at Major International Conference
05/21/08
Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in
Lancet Oncology
11/08/07
Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
10/23/07
Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
10/17/06
Jennerex and Green Cross Enter Agreement to Develop and Commercialize JX-594 In South Korea